GLP1R and metabolic disease: The GCGR/GLP-1R dual agonists mazdutide and survodutide have also advanced to Phase III clinical trial, while efinopegdutide has progressed to Phase II clinical development.4 Additionally, a recent study published in Nature reported a strong correlation between constitutive GCGR activation and elevated blood glucose levels in birds.5 This finding not only underscores the functional diversity of GCGR across species but also offers new insights into its role in human metabolic diseases.